Sequenom's consumables business as well as sales of its MassArray system and related products led the revenue uptick, and its CEO reported "significant" progress on the development of its Trisomy 21 test.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.